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Cerebrospinal fluid analysis differentiates between 
relapsing-remitting and secondary progressive 
multiple sclerosis
Peter J H  Jongen, Karel J B Lamers, Wim H  Doesburg, W im  A  J G  Lem m ens,
Otto R Hommes
Abstract
Objectives—To find whether CSF analysis 
may differentiate between relapsing- 
remitting and secondary progressive mul­
tiple sclerosis.
Methods—In 17 patients with relapsing- 
remitting and 16 patients with secondary 
progressive multiple sclerosis, all without 
current or recent relapses, albumin CSF; 
peripheral blood ratio, mononuclear cell 
number, CD4+, CD8+, and B1+ subsets, 
CD4+:CD8+ ratio, IgG, IgG index, IgM, 
IgM index, complement components C3 
and C4, and C3 and C4 indices, myelin 
basic protein, neuron specific enolase, 
SI00, and lactate were determined. For 
each measure the statistical distance 
measure D2 was calculated. For computa­
tion of a discriminant score variables with 
a P value^0.IS were included (two sided 
univariate t test). These were albumin 
CSF: peripheral blood ratio, mononuclear 
cell number, IgM, IgM index, C3, C4, neu­
ron specific enolase, SI00, and lactate. 
Simultaneous distributions o f the vari­
ables were compared between both groups 
(multivariate t test) and a discriminant 
score was computed (linear discriminant 
analysis).
Results—The discriminant score allo­
cated all 14 relapsing-remitting patients to 
the relapsing-remitting group (positive 
score) and 12 of 13 secondary progressive 
patients to the secondary progressive 
group (negative score). One secondary 
progressive patient was allocated to the 
relapsing-remitting group«
Conclusions—Patients with relapsing- 
remitting or secondary progressive multi­
ple sclerosis differ in CSF profile and CSF 
analysis may help to differentiate between 
relapsing-remitting and secondary pro­
gressive multiple sclerosis.
(7 Neurol Neurosurg Psychiatry 1997;63:446-451)
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Multiple sclerosis is a presumed autoimmune 
disease of the CNS with focal inflammation 
and demyelination as the major pathological 
features. The pathogenesis of CNS lesions 
consists of a series of events. Increased perme­
ability of the blood-brain barrier enables
mononuclear cells to enter the CNS paren­
chyma and to form perivascular infiltrates.12 
The immune mechanisms then occurring 
involve T  cellSj macrophages, and antibodies.1“3 
The inflammatory immune attack is thought to 
result in demyelination.4 Whereas inflamma­
tion is not necessarily associated with struc­
tural damage, demyelination leads to persistent 
deficits, producing a perm anent interruption in 
axonal conduction .14 Later in the disease proc­
ess axonal and glial damage also occur.15
Basically, these processes are reflected by 
changes in the composition of the CSF. Thus 
an increased CSF:peripheral blood ratio for 
albumin represents increased permeability of 
the blood-brain barrier (transudation), and 
raised mononuclear cell numbers in CSF 
reflect the cellular component of the 
inflammation.* The presence of CSF specific 
oligoclonal bands and increased IgG and IgM 
indices indicate intrathecal immunoglobulin 
production .6 In addition, intrathecal activation 
of the complement system leads to altered 
CSF concentrations of the complement com­
ponents C3 or C4 or their intrathecal 
synthesis.7 s Increased CSF concentration of 
myelin basic protein mirrors demyelination 
Myelin basic protein values are raised in 
patients with clinically active multiple sclerosis 
and fall significantly after methylprednisolone 
treatment.10 N euron specific enolase is a 
marker for neuronal damage and CSF concen­
trations are increased in various disorders of 
the C N S .11"13 The nervous system specific 
S I00 protein is notably present in astrocytes 
and oligodendrocytes, and CSF S I 00 is a 
marker for glial dam age .11 1214-16 In  patients 
with multiple sclerosis S 100  concentrations 
are higher during active disease.14 15 Subse­
quently, the CSF lactate concentration in­
creases as a result of intracerebral processes 
involving ischaemia.6 17
Most patients with multiple sclerosis s tart 
with a relapsing-remitting course. After five to
10 years most patients gradually transgress to 
the secondary progressive phase .5 H istopatho- 
logical and M R I evidence indicate tha t pa tho­
genic and pathological differences exist b e ­
tween relapsing-remitting and secondary 
progressive multiple sclerosis.1819 By contrast 
with the relapsing-remitting phase the p ro ­
gressive phase shows less evidence for an 
autoimmune process.5 Data from M R I an d  
N M R  spectroscopy show that the chronic p ro ­
gression is related to neuronal and  axonal
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Table 1 Cerebrospinal fluid measures in relapsing-remitting (RR) and secondary 
progressive (SP) patients
Median values R R v S P
Units RR (n~ 17) SP (n~16)
• JL\yJui CffwC
values D 2 P  value
Transudation:
Albumin CSF:PB 4.3 5.0 1.8-7.0 0.39 0.09
Cellular immunology:
Mononuclear cells *d 8 3 0-4 0.61 0.03
CD4+ % 71 71 50-80 0.03 0.63
CD8+ % 20 21 15-37 0.004 0.86
CD4+/CD8+ 3.4 3.4 1-4 0.001 0.96
B1 + % 3 3 0-5 0.06 0.50
Humoral immunology:
IgG mg/1 37 43 11-38 0.11 0.36
IgG index 0.83 0.74 0.36-0 .60 0.09 0.79
IgM mg/1 0.6 0.4 0 .1 -0 .4 0.36 0,10
IgM index 0.07 0,05 0.01-0 .07 0.27 0.15
Complement C3 mg/1 2.0 2.2 0 ,9-6 .7 0.41 0.08
Complement C3 0.57 0.60 0.32-0 .77 0.004 0.86
index
Complement C4 mg/1 1.3 1.5 0.6-3 .5 0.28 0.14
Complement C4 0.92 1.07 0.4-1 .7 0.04 0.58
index
Demyelination:
MBP ug/1 0.6 0.5 0 .2-1 .2 0.19 0.22
Neuronal damage:
NSE ug/1 6.2 4.9 2.0-10.0 0.30 0.12
Glial damage:
S100 Ug/1 1.5 1.2 0 .7-2 .0 0.29 0.13
Metabolic change:
Lactate ^mol/I 1660 1785 1380-1900 0.45 0.08
Median values, reference values, and statistical distance D2 are given for each variable, PB 
peripheral blood; MBP = myelin basic protein; NSE = neuron specific enolase.
damage.5 1819 In view of these differences* 
drugs that are effective in the relapsing- 
remitting phase are not necessarily so in the 
secondary progressive phase* and drug re­
search involves separate trials for relapsing- 
remitting and secondary progressive multiple 
sclerosis. Thus the im m unomodulating agent 
copolymer- 1 has been shown to lessen disabil­
ity in relapsing-remitting patients but was not 
effective in the chronic progressive phase ,20 21 
As the number of immunotherapies is ex­
pected to increase in the near future* accurate 
distinction between relapsing-remitting and 
secondary progressive multiple sclerosis be­
comes more relevant, to optimise the applica­
tion of possibly expensive drugs, Importantly* 
however, at a certain stage of the disease 
course various circumstances may seriously 
hinder the differentiation between relapsing- 
remitting and secondary progressive multiple 
sclerosis—namely* clinical fluctuations in be­
tween relapses in the relapsing-remitting 
phase; the insidious character of the transgres­
sion to the secondary progressive phase; and 
the occurrence of stable periods in the 
secondary progressive phase. As a conse­
quence* in individual patients the secondary 
progressive phase of the disease can often only 
be diagnosed reliably in retrospect.
Considering the above* we studied whether 
detailed CSF examination might differentiate 
between relapsing-remitting and secondary 
progressive multiple sclerosis. We measured a 
range of CSF variables in patients with 
clinically established relapsing-remitting or 
secondary progressive multiple sclerosis* and 
used discriminant analysis to develop an 
allocation index that distinguishes between the 
relapsing-remitting and secondary progressive 
type.
Patients and methods
PATIENTS
Thirty three patients were studied* 17 having 
been diagnosed as having relapsing-remitting 
disease and 16 as having secondary progressive 
disease on clinical grounds* in accordance with 
a recent consensus report.22 Inclusion criteria 
were (a) clinically definite multiple sclerosis/ 3
(b) for relapsing-remitting patients: two or 
more relapses in the preceding two years* and 
(ic) for secondary progressive patients: at least 
six months of continuous progression in the 
year before the study* with or without relapses. 
Exclusion criteria were (a) relapse in the three 
months before the study* (6) corticosteroid 
treatment in the two months before the study*
(c) any previous immunosuppressive treat­
ment* including cyclophosphamide* azathio- 
prine* and cyclosporine A* and (d) contraindi­
cation for lumbar puncture. In  each patient 
age* disease duration* number of relapses* and 
total methylprednisolone dose in the two years 
before the study were ascertained. In second­
ary progressive patients the duration of the 
secondary progressive phase was determined. 
On neurological examination one of us (ORH)* 
an experienced neurologist* determined the 
expanded disability status scale (EDSS) score 
(24) with a 0.5 point interval—based on 
assessment of the neurological (Kurtzke) and 
the Scripps neurological rating scales 
(SNRS) .24 25 The progression rate was calcu­
lated as the EDSS score:disease duration ratio. 
The study protocol was approved by the ethics 
committee of the University Hospital Ni­
jmegen. Written informed consent was ob­
tained from each patient.
CEREBROSPINAL FLUID EXAMINATIONS
Seven types of pathogenic or pathological 
processes were considered as potentially differ­
ent between the relapsing-remitting and the 
secondary progressive phase of the disease: 
blood-brain barrier disturbance* cellular im­
mune processes* humoral immune processes* 
demyelination* neuronal damage* glial damage* 
and metabolic changes. Measurements in CSF 
corresponding to these processes were albumin 
CSF:peripheral blood ratio* mononuclear cell 
number* CD4+* CD8+* and B1+ subset 
percentages* CD4+:CD8+ ratio* IgG* IgG 
index* IgM* IgM index* complement compo­
nent C3* complement component C3 index* 
complement component C4* complement 
component C4 index* myelin basic protein* 
neuron specific enolase* S100* and lactate. 
Lumbar punctures were performed at level 
L5-S1 according to standard procedures with 
an atraumatic conical elliptic shaped spinal 
needle 22G 103 mm with introducer (Poly­
medic). All punctures were performed between 
1100 and 1300 hours and about 10 ml colour­
less CSF was obtained. Simultaneously* pe­
ripheral venous blood was drawn via cubital 
venapuncture. Cell counting and determina­
tion of lymphocyte subpopulations were imme­
diately performed. For the remaining measure­
ments paired samples of CSF and serum were 
stored at -70°C. The lymphocyte subsets were 
assayed by flow cytometry on a FACS II cell
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Table 2 Characteristics of study population
Relapsing-rem iiting 
( n 7)
Secondary progressive 
0i=16)
P value 
t test
M7F 5/12 8/8
Age (y) 36.2 (8.1) 40.2 (7.5) 0.15
EDSS 3.0 (1.1) 4.1 (1.3) 0.01
Scripps NRS 72.7 (12,5) 62.1 (12.2) 0.02
Relapses in 2 years before study 2.8 (0.8) 0.6 (0.8) 0.0001
Disease duration (y) 6.4 (4.3) 9.2 (3.8) 0.06
Progression rate 0.7 (0.6) 0.5 (0.2) 0.18
Progressive phase (y) 3.9 (1.9)
EDSS = expanded disability status scale; NRS = neurological rating scale. 
Values are given as mean (SD).
sorter (Beeton Dickinson, USA) according to a 
method described by Dux etal,26 CD3+, CD4+ 
(helper-inducer cell)* CD 8+ (suppressor- 
cytotoxic cell) and CD20+ (B1 cell) were ana­
lysed. Fluorescein labelled antibodies were 
purchased from Dakopatt (Denmark). For dis­
tinguishing lymphocytes from other cells 
(erythrocytes) the lymphocyte marker CD45 
CYQ (IQPj Groningen, The Netherlands) was 
always included in each test. IgG, IgM, and 
albumin were determined by immunoneph- 
elometry on a COB AS FARA II apparatus 
(Hoffman La Roche, Switzerland) with the 
exception of CSF IgM, which was assayed by 
an enzyme linked immunosorbent assay 
(ELISA) method as described by Jongen et 
al.2128 Complement components C3 and C4 
were measured by immunonephelometry on a 
Hyland lasernephelometer using antiserum 
from Dakopatt (Denmark) .27 Myelin basic pro­
tein was determined by a double antibody 
radioimmunoassay kit according to the instruc­
tions of the manufacturer (Diagnostic Systems 
Laboratories^, Webster Texas, USA) .29 Neuron 
specific enolase measurement was performed 
by an immunoluminometric assay on an 
UA-MAT analyser according to the instruc­
tions of the manufacturer (Sangtec Medical, 
Sweden). Age related values for these CNS 
specific proteins in CSF in our laboratory have 
been published.30 S100 was determined by a 
double monoclonal antibody enzyme immu­
noassay according to the procedure published 
by Lamer s et aV1 The index value of a distinct 
protein= protein CSFxalbumin serum:protein 
serumXalbumin CSF. Table 1 presents the ref­
erence values for CSF indices (P5-P95), as 
established in our laboratory.
STATISTICAL ANALYSIS
For the 18 CSF variables univariate and multi­
variate statistical analyses were performed after 
logarithmic transformation.31 For each CSF 
variables (table 1 ) the median value was calcu­
lated for both groups (relapsing-remitting and 
secondary progressive) by interpolation from 
the cumulative sample distributions. To rank 
the indices after their discriminating power 
(between relapsing-remitting and secondary 
progressive) the usual statistical distance meas­
ure D 2 was calculated,
D 2=((mean(log(x)RR)-mean(log(x)SP))/SDp)2
with SDP being the pooled SD (after 
logarithmic transformation) over both groups.
a)
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Figure Î Cerebrospinal fluid discriminant score values in 
Î 7 patients with relapsing-remitting (RR) and 16 patients 
with secondary progressive (SP) multiple sclerosis.
For each variable the statistical comparison 
of the sample distribution between both groups 
was done by univariate two sample t test (two 
sided a=0.05). For the computation of an allo­
cation index (=discriminant score) we tried to 
use fewer variables. This was achieved by 
inclusion only of those variables for which the 
P value of the two sided univariate t test was 
^0.15. The simultaneous distributions of these 
variables were compared between both groups 
by means of the multivariate r test (Hotelling’s 
test). A discriminant score was computed 
according to the method of linear discriminant 
analysis (Fisher’s equal probabilities). A sec­
ond discriminant analysis was performed on 
those selected variables assumed to be determi­
nable at routine laboratories.
Results
PATIENT CHARACTERISTICS
Table 2 shows patient characteristics. As a 
group secondary progressive patients had 
significantly higher EDSS scores, lower SNRS 
scores* and a lower number of relapses than 
relapsing-remitting patients. All but three 
patients—one relapsing-remitting and two sec­
ondary progressive—had received methylpred- 
nisolone in the two years before the study, No 
patient had received prednisone in these years, 
The total methylprednisolone doses in the two 
years before the study did not differ signifi­
cantly between relapsing-remitting and sec­
ondary progressive patients.
DISCRIMINANT ANALYSIS
Table 1 shows median values of CSF variables, 
reference values, D 2 after logarithmic transfor-
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Table 3 Calculation of CSF discriminant scores in two patients
8
Multiplication Contribution to
Variable Value Log factor discriminant score Cumulative score
Patient A 6Intercept -5 .9 5 -5 .9 5
Q albumin 4.30 1.4586 14.37 20.96 15.01
MNC 11.00 2.3979 1.15 2.75 17.76
IgM 0.30 -1 .2040 6.13 -7 .3 8 10.37
IgM index 0.07 -2 .6593 -4 .2 5 11.30 21.76 4 ------
C3 1.70 0.5306 -2 1 .0 2 -1 1 .1 5 10.52
C4 0,60 -0 .5108 -4 .5 2 2.31 12.83
NSE 7.10 1.9604 6.02 11.80 24.63
S100 0.66 -0 .4186 2.23 -0 .9 3 23.70 0) A
Lactate 1832 7.5132 -2 .6 6 -2 0 .0 2 3.68 o 2
Discriminant +3.68 ow
score LL -
Allocation to RR CO( J
Patient B x s 0
Intercept -5 .9 5 <D
+ - *
Q albumin 16.90 2.8273 14.37 40.63 34.68 01 «<** 1
MNC 9.00 2.1972 1.15 2.52 37,19
fete
V)
IgM 2.40 0.8755 6.13 5.37 42.56 tt)orIgM index 0.10 -2 .3026 -4 ,2 5 9.78 52.34 - 2 ------
C3 7.00 1.9459 -2 1 .0 2 -4 0 .9 0 11.45
C4 3.20 1.1632 -4 .5 2 -5 .2 6 6.19
NSE 5.23 1.6536 6.02 9.95 16.14
S100 0.71 -0 .3496 2.23 -0 .7 8 15.36 - 4Lactate 1971 7.5863 -2 .6 6 -2 0 .21 -4 .8 5
Discriminant -4 .8 5
score —
Allocation to SP
a
MNC = Mononuclear cells; C3 = complement component C3; C4 = complement component C4  ^
NSE = neuron specific enolase; Q albumin = CSF: peripheral blood albumin ratio.
mation> and t test P values. Based on P values 
the following variables were selected for 
discriminant analysis: CSF:peripheral blood 
albumin ratio (P=0.09)j m ononuclear cell 
number (P=0.03)3 IgM  (P=0,10 )3 IgM  index 
(P=0.15)j complement com ponent C3 
(P=0.08)j> complement com ponent C4 
(P=0.14)j neuron specific enolase (P=0.12)a 
S I00 (P=0.13)j and lactate (P=0.08). Discri­
minant analysis resulted in a discriminant 
score (allocation index) composed of these 
nine variables. Using this score all 14 
relapsing-remitting patients were allocated to 
the relapsing-remitting group (positive discri­
minant score)* and 12 of 13 secondary 
progressive patients to the secondary progres­
sive group (negative discriminant score). One 
secondary progressive patient was allocated to 
the relapsing-remitting group. Table 3 shows 
examples of calculation of discriminant scores. 
Figure 1 shows the discriminant scores for the 
33 patients. Notably^ inclusion of nine vari­
ables by means of a stepwise discriminant 
analysis (significance levels “entry” and "stay” 
both 0.15)— in which only patients were 
included with complete information on all 
variables—resulted in almost the same set of 
variables. Only lactate was replaced by myelin 
basic protein3 probably due to leaving out five 
patients with missing values on lactate. A sec­
ond discriminant analysis was performed on 
those selected variables assumed to be deter­
minable at routine laboratories. This analysis 
included only the CSF variables CSF:periph- 
eral blood albumin ratio3 m ononuclear cell 
number, IgM* IgM indexa and lactate. T he 
scores of the secondary progressive group 
overlapped those of the relapsing-remitting 
groups as seven of the 13 secondary progres­
sive patients had a score falling in the 
relapsing-remitting range (fig 2).
-8
9
o
oo
o
o
RR SP
Figure 2 Values of a restricted CSF score in 17 patients 
with relapsing-remitting (RR) and 16 patients with 
secondary progressive (SP) multiple sclerosis. Values were 
computed from variables considered to be determinable at 
routine laboratories ( albumin ratio, mononuclear cell 
number, CSF IgM, ïgM  index, and C SF lactate).
D iscussion
Recent reports underline the importance of 
CSF analysis in the differential diagnosis of 
CNS disorders.32 33 T he combination of several 
CSF measurements greatly improves the differ­
ential diagnosis of multiple sclerosis versus 
other neurological disorders and CSF analysis 
supports the diagnostic classification of multi­
ple sclerosis.23 34 We investigated whether de­
tailed CSF analysis may differentiate between 
the relapsing-remitting and secondary progres­
sive phase of the disease^ and we performed a 
discriminant analysis of CSF variables in these 
patients. The variables studied reflected tran- 
sudation5 cellular and humoral immune proc­
ess es3 demyelination3 neuronal and glial dam- 
age3 and hypoxia. The discriminant score 
allocated 26 out of 27 patients to either the 
relapsing-remitting or secondary progressive 
group in agreement with the clinical diagnosis. 
This finding implies that patients diagnosed as 
having a relapsing-remitting or secondary pro­
gressive course on clinical grounds also differ 
with respect to CSF profile^ and that the 
discriminant score may be of help in classifying 
individual patients as being relapsing-remitting 
or secondary progressive.
An important aspect of our study is that we 
only included relapsing-remitting patients who 
had had no current or recent clinical relapses. 
So our data are not confounded by abnormali­
ties resulting from events related to exacerba­
tion. On follow up the first exacerbations 
occurred at a mean of 137 (SD 103) days after
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CSF sampling, the earliest relapse occurring at 
41 days, for which reason it is unlikely that CSF 
findings reflect a subclinical increase of disease
activity.
Pathological and MRI studies in multiple 
sclerosis suggest that various pathogenic and 
pathological processes may be at work 
simultaneously.5 1819 Conceivably, the activity 
of each of these processes in the secondary 
progressive phase may be only slightly different 
from that in the relapsing-remitting phase, 
which means that for a given variable CSF 
concentrations in the secondary progressive 
phase may not differ significantly from those in 
the relapsing-remitting phase. For this reason 
we did not search for a single variable that 
might differerentiate between the two groups; 
nor did we try to detect significances for single 
variables. These might be found in large study 
populations, but, as expected, individual values 
largely overlap and are of little use as a 
discriminating tool. By contrast, our study was 
designed to detect changes in a complex CSF 
profile in a relatively small group of patients 
and thus to develop a discrimination index that 
may be used in individual patients. Thus we 
found that nine of the 18 variables tested 
(50%) had a P value ^0.15 and thus 
contributed to the discrimination index, As 
CSF measurement of neuron specific enolase, 
S100, and the complement components C3 
and C4 may not be performed routinely in 
hospital laboratories, we determined the dis­
criminating value of the CSF:peripheral blood 
albumin ratio, mononuclear cell number^ IgM, 
IgM index* and lactate. This second score 
seemed to be of limited use given that seven of 
the 13 secondary progressive patients had 
scores in the relapsing-remitting range.
The establishment of a relation between a 
clinical variable of multiple sclerosis and 
changes of CSF mononuclear cells, immu­
noglobulins or complement components is 
beset with difficulties, as immunotherapies may 
have long lasting effects on CSF immune 
indices.35 In our study no patient had received 
any cytotoxic agent, nor had recently used cor­
ticosteroids. Moreover, the total steroid dose in 
the two years before the study did not differ 
between relapsing-remitting and secondary 
progressive patients. For these reasons we think 
that we measured intrinsic differences and not 
treatment induced artifacts.
Generally, the relapsing-remitting patients 
had increased mononuclear cell numbers and 
IgM, as well as neuron specific enolase and 
S 100 . The results for IgM in these patients 
seem not to reflect simple blood-brain barrier 
damage, as the IgM index tended to be higher 
than in secondary progressive patients. Sec­
ondary progressive patients generally had 
increased lactate and albumin with consequent 
increases of C3 and C4, the last probably due 
to blood-brain barrier damage rather than local 
synthesis, as the indices are normal. The 
significantly lower mononuclear cell numbers 
in the CSF of secondary progressive patients 
may indicate that the inflammatory component 
of the disease “burns out” during its natural 
course. Our findings on the albumin ratio tend
to suggest that damage to the blood-brain bar­
rier in the secondary progressive phase is rather 
more diffuse than the more striking punctate 
abnormalities which are seen in gadolinium 
MRI studies of the relapsing-remitting form. 
Others have also shown that the impairment of 
the blood-brain barrier in secondary progres­
sive patients is worse than in relapsing- 
remitting patients .30 For the finding that CSF 
IgM in secondary progressive patients tended 
to be lower than in relapsing-remitting patients 
(means 0,4 ^ 0.6, P = 0.10), Sindic et al reported 
a raised IgM index in 32% of 80 patients with 
multiple sclerosis, but in none of 10 patients 
with a history of multiple sclerosis exceeding 
15 years.37 Two other studies registered raised 
IgM indices at a decreasing rate with an 
increasing duration of disease .38 39 Although the 
lower IgM values in our secondary progressive 
patients may partly relate to duration of 
disease, the discriminant score was not related 
to disease duration (data not shown).
Concentrations of C4 in CSF made a large 
contribution to the differentiation index in that 
lower C4 is related to the relapsing-remitting 
course. As early as 1965 it was shown that CSF 
complement activity is lower in patients with 
multiple sclerosis than in controls, and die 
lowest during acute deterioration .40 Moreover, 
patients with raised C SF y-globulin content 
showed lower complement activity than those 
with normal C SF y-globulin, and the comple­
ment activity was significantly correlated with 
the total protein concentration in controls, but 
not in the patients with multiple sclerosis .4Q 
Recent CSF studies in patients with acute optic 
neuritis and multiple sclerosis confirmed previ­
ous reports on intrathecal complement 
activation.8 Therefore., we think that one expla­
nation for the relatively low C4 concentrations 
in our relapsing-remitting group may be steady 
C4 consumption by immune mediated proc­
esses in between relapses. On the other handj it 
is conceivable that C4 discrepancies reflect 
immunogenetic differences. In  a recent study 
on complement gene polymorphisms Franci- 
otta et al reported that patients with relapsing- 
remitting multiple sclerosis have a significantly 
higher frequency of C4AQ0 (null) allele than 
primary progressive patients .41 Moreover, a 
structural gene deletion was present in 45% of 
relapsing-remitting patients with the C4AQ0 
allele.41 As complement factors contribute to 
elimination of immune complexes^ deficiency 
of a functional complement component could 
predispose to multiple sclerosis, and more spe­
cifically to the occurrence of virus induced 
relapses.
The CNS tissue markers S I 00 and neuron 
specific enolase also contributed to the discri­
minant score, in that high CSF concentrations 
suggested relapsing-remitting diagnosis. As our 
patients were sampled in a relapse free period, 
this finding suggests that in between relapses 
tissue damage is more pronounced that in the 
progressive phase. Recently Massaro et al 
performed a five week follow up study of CSF 
changes during and after an exacerbation; 
S I00  concentrations increased early after
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relapses and remained increased during the 
whole study period.15
To conclude^ we calculated a discriminant 
score that differentiates between relapsing- 
remitting and secondary progressive multiple 
sclerosis. From a pathogenic and pathophysi­
ological point of view, our data indicate that a 
combination of cellular and antibody medi- 
atedj immune processes involving complement 
lead to damage of neurons and glia3 and that 
these processes are more pronounced in 
relapsing-remitting than in secondary progres­
sive multiple sclerosis. We speculate that moni­
toring of the discriminant score will prove use­
ful in the early and accurate diagnosis of the 
secondary progressive versus the relapsing- 
remitting phase in individual patients. How­
ever, as we included in our study only patients 
with an unquestionable clinical course, pro­
spective studies are needed to validate the dis­
criminant score and to assess its applicability in 
patients just transgressing from the relapsing- 
remitting to the secondary progressive phase.
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